DK1645631T3 - Neisseria antigener og præparater - Google Patents

Neisseria antigener og præparater

Info

Publication number
DK1645631T3
DK1645631T3 DK05077865T DK05077865T DK1645631T3 DK 1645631 T3 DK1645631 T3 DK 1645631T3 DK 05077865 T DK05077865 T DK 05077865T DK 05077865 T DK05077865 T DK 05077865T DK 1645631 T3 DK1645631 T3 DK 1645631T3
Authority
DK
Denmark
Prior art keywords
preparations
neisseria antigens
antigens
proteins
neisseria
Prior art date
Application number
DK05077865T
Other languages
Danish (da)
English (en)
Inventor
Claire Fraser
Erin Hickey
Vega Masignani
Mariarosa Mora
Jeremy Petersen
Mariagrazia Pizza
Rino Rappuoli
Giulio Ratti
Enzo Scalato
Maria Scarselli
Herve Tettelin
J Craig Venter
Cesira Galeotti
Guido Grandi
Original Assignee
Novartis Vaccines & Diagnostic
Inst Genomic Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27574612&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1645631(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Vaccines & Diagnostic, Inst Genomic Research filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of DK1645631T3 publication Critical patent/DK1645631T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK05077865T 1998-05-01 1999-04-30 Neisseria antigener og præparater DK1645631T3 (da)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US8375898P 1998-05-01 1998-05-01
US9486998P 1998-07-31 1998-07-31
US9899498P 1998-09-02 1998-09-02
US9906298P 1998-09-02 1998-09-02
US10374998P 1998-10-09 1998-10-09
US10379498P 1998-10-09 1998-10-09
US10379698P 1998-10-09 1998-10-09
US12152899P 1999-02-25 1999-02-25
PCT/US1999/009346 WO1999057280A2 (en) 1998-05-01 1999-04-30 Neisseria meningitidis antigens and compositions

Publications (1)

Publication Number Publication Date
DK1645631T3 true DK1645631T3 (da) 2008-02-18

Family

ID=27574612

Family Applications (2)

Application Number Title Priority Date Filing Date
DK05077865T DK1645631T3 (da) 1998-05-01 1999-04-30 Neisseria antigener og præparater
DK99922752T DK1093517T3 (da) 1998-05-01 1999-04-30 Neisseria-meningitidis-antigener og præparater

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK99922752T DK1093517T3 (da) 1998-05-01 1999-04-30 Neisseria-meningitidis-antigener og præparater

Country Status (17)

Country Link
US (9) US7576176B1 (de)
EP (23) EP2261356A3 (de)
JP (9) JP5102414B2 (de)
CN (3) CN1210305C (de)
AT (2) ATE376591T1 (de)
AU (1) AU761780B2 (de)
BR (1) BR9910089A (de)
CA (2) CA2650642A1 (de)
CY (2) CY1109649T1 (de)
DE (2) DE69938302T2 (de)
DK (2) DK1645631T3 (de)
ES (3) ES2537575T3 (de)
HK (1) HK1090382A1 (de)
MX (4) MX343744B (de)
NZ (4) NZ527182A (de)
PT (3) PT1093517E (de)
WO (1) WO1999057280A2 (de)

Families Citing this family (198)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT909323E (pt) 1996-01-04 2007-06-04 Novartis Vaccines & Diagnostic ''bacterioferritina de helicobacter pilori''
CA2266656A1 (en) 1996-09-17 1998-03-26 Chiron Corporation Compositions and methods for treating intracellular diseases
EP1900818A3 (de) * 1997-11-06 2008-06-11 Novartis Vaccines and Diagnostics S.r.l. Neissersche Antigene
US6914131B1 (en) 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
EP2261356A3 (de) * 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Antigene und Zusammensetzungen gegen Neisseria meningitidis
US20070026021A1 (en) * 1998-05-01 2007-02-01 Chiron S.R.I. Neisseria meningitidis antigens and compositions
US6756493B1 (en) 1998-09-01 2004-06-29 Antex Biologics, Inc. Nucleic acid sequence and uses thereof
US6693186B2 (en) 1998-09-01 2004-02-17 Antex Biologics Inc Neisseria meningitidis polypeptide, nucleic acid sequence and uses thereof
US6610306B2 (en) 1998-10-22 2003-08-26 The University Of Montana OMP85 protein of neisseria meningitidis, compositions containing the same and methods of use thereof
WO2000034482A2 (en) 1998-12-08 2000-06-15 Smithkline Beecham Biologicals S.A. Novel compounds derived from neisseria meningitidis
WO2000042193A1 (en) * 1999-01-15 2000-07-20 Smithkline Beecham Biologicals S.A. Neisseria meningitidis antigen
WO2000042192A1 (en) * 1999-01-15 2000-07-20 Smithkline Beecham Biologicals S.A. Neisseria meningitidis polypeptide basb052
EP1149164A2 (de) 1999-01-22 2001-10-31 SmithKline Beecham Biologics SA Neisseria meningitidis polypeptide
WO2000043518A1 (en) * 1999-01-22 2000-07-27 Smithkline Beecham Biologicals S.A. Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies
GB9902084D0 (en) * 1999-01-29 1999-03-24 Smithkline Beecham Biolog Novel compounds
GB9902937D0 (en) * 1999-02-10 1999-03-31 Smithkline Beecham Biolog Novel compounds
DE60015084T2 (de) 1999-02-26 2006-02-16 Chiron S.R.L. Verbesserung der bakterizidaktivität von neisseria antigenen mit cg enthaltende oligonukleotiden
EP2270169A3 (de) * 1999-03-12 2011-06-15 GlaxoSmithKline Biologicals SA Antigene Polypeptide aus Neisseria Meningitidis, dafür kodierende Polynukleotide und entsprechende schützende Antikörper
AU2004240199B2 (en) * 1999-04-30 2007-05-17 Novartis Vaccines And Diagnostics S.R.L. Conserved Neisserial antigens
CA2372235A1 (en) 1999-04-30 2000-11-09 Rino Rappuoli Conserved neisserial antigens
GB9911683D0 (en) * 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
AU2013203304B2 (en) * 1999-05-19 2014-10-09 Glaxosmithkline Biologicals S.A. Combination Neisserial compositions
CN100338218C (zh) * 1999-05-19 2007-09-19 启龙股份公司 组合式奈瑟球菌组合物
AU2013200678B2 (en) * 1999-05-19 2014-08-21 Glaxosmithkline Biologicals S.A. Combination Neisserial compositions
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
AU2003270970B2 (en) * 1999-08-03 2005-05-26 Smithkline Beecham Biologicals S.A. Vaccine composition
EP2975127A1 (de) 1999-10-29 2016-01-20 GlaxoSmithKline Biologicals SA Neisseria antigenpeptide
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
WO2001038350A2 (en) 1999-11-29 2001-05-31 Chiron Spa 85kDa NEISSERIAL ANTIGEN
PT1248647E (pt) * 2000-01-17 2010-11-18 Novartis Vaccines & Diagnostics Srl Vacina de vesícula da membrana externa (omv) compreendendo proteínas de membrana externa de n. meningitidis do serogrupo b
CN1419564A (zh) 2000-01-25 2003-05-21 昆士兰大学 包含脑膜炎奈瑟氏球菌表面抗原NhhA的保守区域的蛋白质
WO2001064922A2 (en) 2000-02-28 2001-09-07 Chiron Spa Heterologous expression of neisserial proteins
MXPA03000822A (es) 2000-07-27 2004-11-01 Childrens Hosp & Res Ct Oak Vacunas para proteccion de espectro amplio contra enfermedades causadas por neisseria meningitidis.
EP2189473A3 (de) 2000-10-27 2010-08-11 Novartis Vaccines and Diagnostics S.r.l. Nukleinsäure und Proteine von Gruppen A und B Streptokokken
US7250172B2 (en) 2001-01-31 2007-07-31 University Of Iowa Research Foundation Vaccine and compositions for the prevention and treatment of neisserial infections
US7261901B2 (en) 2001-01-31 2007-08-28 University Of Iowa Research Foundation Vaccine and compositions for the prevention and treatment of neisserial infections
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
AU2002252638A1 (en) * 2001-04-17 2002-10-28 Children's Hospital Oakland Research Institute Molecular mimetics of meningococcal b epitopes which elicit functionally active antibodies
EP2332573A1 (de) 2001-05-31 2011-06-15 Novartis Vaccines and Diagnostics, Inc. Chimäre Alphavirus-Replikonpartikel
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
DE60236596D1 (de) 2001-07-27 2010-07-15 Novartis Vaccines & Diagnostic Antikörper gegen das meningokokken adhäsin app
GB0121591D0 (en) * 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AU2012202488B2 (en) * 2001-09-06 2014-01-16 Glaxosmithkline Biologicals S.A. Hybrid and tandem expression of Neisserial proteins
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
WO2003028661A2 (en) * 2001-10-03 2003-04-10 Chiron Corporation Adjuvanted meningococcus compositions
US7838015B2 (en) * 2001-10-03 2010-11-23 Novartis Vaccines And Diagnostics, Inc. Adjuvanted meningococcus compositions
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
NZ546711A (en) 2001-12-12 2008-06-30 Chiron Srl Immunisation against chlamydia trachomatis
US7501134B2 (en) 2002-02-20 2009-03-10 Novartis Vaccines And Diagnostics, Inc. Microparticles with adsorbed polypeptide-containing molecules
EP1524992B1 (de) 2002-08-02 2015-03-04 GlaxoSmithKline Biologicals s.a. Impfstoffzusamensetzungen die l2 und/oder l3 immunotyp lipooligosaccharids von lgtb- neisseria meningitidis enthalten
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
PT2351579T (pt) * 2002-10-11 2016-12-22 Novartis Vaccines And Diagnostics S R L Vacinas polipeptídicas para proteção ampla contra linhagens meningocócicas hipervirulentas
NZ539706A (en) 2002-11-01 2008-03-28 Glaxosmithkline Biolog Sa Immunogenic compositions comprising a dried solid or high viscosity liquid formulation of inactivated polio virus (IPV) that retains immunogenicity
US7807802B2 (en) 2002-11-12 2010-10-05 Abbott Lab Polynucleotides for the amplification and detection of Chlamydia trachomatis and Neisseria gonorrhoeae
EP1562982B1 (de) 2002-11-15 2010-05-05 Novartis Vaccines and Diagnostics S.r.l. Unerwartete oberflächenproteine in neisseria meningitidis
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
EP1585542B1 (de) 2002-12-27 2012-06-13 Novartis Vaccines and Diagnostics, Inc. Immunogene zusammensetzungen enthaltend phospholipid
WO2004067030A2 (en) 2003-01-30 2004-08-12 Chiron Srl Injectable vaccines against multiple meningococcal serogroups
WO2004087153A2 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
WO2004094596A2 (en) * 2003-04-16 2004-11-04 Wyeth Holdings Corporation Novel immunogenic compositions for the prevention and treatment of meningococcal disease
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
PT1631264E (pt) 2003-06-02 2009-11-03 Novartis Vaccines & Diagnostic Composições imunogénicas à base de micropartículas biodegradáveis que compreendem um toxóide de difteria e do tétano
WO2005019265A1 (en) 2003-08-13 2005-03-03 Chiron Corporation Improved method of purifying tfpi and tfpi analogs
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
ES2397923T3 (es) 2003-10-02 2013-03-12 Novartis Ag Vacunas líquidas para múltiples serogrupos meningocócicos
CU23236A1 (es) * 2003-12-03 2007-09-26 Ct Ingenieria Genetica Biotech PROTEINA NMB0928 Y SU USO EN FORMULACIONES FARMACéUTICAS P
CU23237A1 (es) * 2003-12-03 2007-09-26 Ct Ingenieria Genetica Biotech PROTEINA NMB1125 Y SU USO EN FORMULACIONES FARMACéUTICAS
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
ATE395356T1 (de) * 2004-06-29 2008-05-15 Ct For Disease Control Dept Of Oberflächenprotein aus neisserien
WO2006078318A2 (en) 2004-07-29 2006-07-27 Novartis Vaccines And Diagnostics Inc. Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
GB0419918D0 (en) * 2004-09-08 2004-10-13 Imp College Innovations Ltd Vaccine
RU2432962C2 (ru) 2005-01-27 2011-11-10 Чилдрен'З Хоспитал Энд Рисерч Сентер Эт Окленд Вакцины с использованием везикул на основе gna 1870 широкого спектра действия для профилактики заболеваний, вызываемых neisseria meningitidis
GB0502096D0 (en) 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
ES2385045T3 (es) 2005-02-18 2012-07-17 Novartis Vaccines And Diagnostics, Inc. Inmunógenos de Escherichia coli uropatogénica
HUE030881T2 (en) 2005-02-18 2017-06-28 Glaxosmithkline Biologicals Sa Meningitis / sepsis-associated escherichia coli proteins and nucleic acids
GB0505996D0 (en) 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
EP1723964A1 (de) * 2005-05-20 2006-11-22 Institut Pasteur Verwendung von Penicillin-bindenden Proteinen, Polynukleotiden oder dagegen gerichteten Antikörpern zur Vorbeugung oder Behandlung von bakteriellen Infektionen
EP2357000A1 (de) 2005-10-18 2011-08-17 Novartis Vaccines and Diagnostics, Inc. Mukosale und systemische Immunisierungen mit Alphavirus-Replikonpartikeln
ES2514316T3 (es) 2005-11-22 2014-10-28 Novartis Vaccines And Diagnostics, Inc. Partículas similares a virus (VLPs) de Norovirus y Sapovirus
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
WO2007066226A2 (en) * 2005-12-06 2007-06-14 Universita Degli Studi Di Padova Methods and compositions relating to adhesins as adjuvants
EP2368569A3 (de) 2006-01-18 2012-05-02 University Of Chicago Zusammensetzungen und Verfahren im Zusammenhang mit Proteinen des Staphylococcus-Bakteriums
ATE539079T1 (de) 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
CU23572A1 (es) * 2006-03-31 2010-09-30 Ct Ingenieria Genetica Biotech Composición farmacéutica que comprende la proteína nmb0938
AU2014268186C1 (en) * 2006-04-26 2017-12-07 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AU2016204760A1 (en) * 2006-04-26 2016-07-28 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
ATE450271T1 (de) 2006-06-12 2009-12-15 Glaxosmithkline Biolog Sa Impfstoff
CN101479293A (zh) 2006-06-29 2009-07-08 诺华有限公司 脑膜炎奈瑟球菌多肽
AU2007285484B2 (en) 2006-08-16 2013-05-02 Novartis Ag Immunogens from uropathogenic Escherichia coli
AR064642A1 (es) * 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
BRPI0816689B1 (pt) 2007-09-12 2021-08-24 Novartis Ag Composição de vacina, kit e método para a confecção de uma composição de vacina para a prevenção ou tratamento de infecção por streptococcus pyogenes
AU2008313424B2 (en) 2007-10-19 2014-05-22 Novartis Ag Meningococcal vaccine formulations
TWI376385B (en) 2007-12-07 2012-11-11 Nat Health Research Institutes Production of lipidated proteins in e. coli
AU2008335457B2 (en) 2007-12-07 2015-04-16 Glaxosmithkline Biologicals S.A. Compositions for inducing immune responses
US7833776B2 (en) * 2007-12-12 2010-11-16 National Health Research Institutes Lipidating sequences and use thereof for producing lipidated proteins in E. coli
US8466259B2 (en) 2007-12-07 2013-06-18 National Health Research Institutes Adjuvants
CN104292312A (zh) 2007-12-21 2015-01-21 诺华股份有限公司 链球菌溶血素o的突变形式
EP2886551A3 (de) 2008-02-21 2015-09-23 Novartis AG Meningokokken-FHBP-Polypeptide
MY150481A (en) 2008-03-03 2014-01-30 Irm Llc Compounds and compositions as tlr activity modulators
US9511131B2 (en) 2008-03-10 2016-12-06 Children's Hospital & Research Center Oakland Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
EP2297578A2 (de) * 2008-05-19 2011-03-23 Novartis AG Impfstofftestverfahren
US20100105875A1 (en) * 2008-06-09 2010-04-29 Maria Scarselli Antibodies against neisserial factor H binding protein
GB0810742D0 (en) * 2008-06-12 2008-07-16 Univ Nottingham Enzyme
US8470340B2 (en) 2008-09-03 2013-06-25 Children's Hospital & Research Center Oakland Peptides presenting an epitope of a domain of factor H binding protein and methods of use
GB0816447D0 (en) * 2008-09-08 2008-10-15 Glaxosmithkline Biolog Sa Vaccine
WO2010049806A1 (en) 2008-10-27 2010-05-06 Novartis Ag Purification method
AU2009329193A1 (en) 2008-12-17 2011-07-14 Novartis Ag Meningococcal vaccines including hemoglobin receptor
US8425922B2 (en) 2009-01-05 2013-04-23 EpitoGenesis, Inc. Adjuvant compositions and methods of use
US8465751B2 (en) 2009-01-12 2013-06-18 Novartis Ag Cna—B domain antigens in vaccines against gram positive bacteria
BRPI1009829A2 (pt) 2009-03-24 2016-11-16 Novartis Ag combinações de proteína de ligação de fator h meningocócico e conjugados de sacarídeos pneumocócicos
JP5597245B2 (ja) 2009-03-24 2014-10-01 ノバルティス アーゲー アジュバント添加した髄膜炎菌ｈ因子結合タンパク質
CA2759400A1 (en) 2009-04-30 2010-11-04 Children's Hospital & Research Center At Oakland Chimeric factor h binding proteins (fhbp) and methods of use
ITMI20090946A1 (it) 2009-05-28 2010-11-29 Novartis Ag Espressione di proteine ricombinanti
US8287880B2 (en) 2009-06-02 2012-10-16 National Health Research Institutes Lipidated vaccine against dengue virus infection
CN102762226A (zh) 2009-06-10 2012-10-31 诺华有限公司 含苯并萘啶的疫苗
EP2443250B8 (de) 2009-06-16 2016-09-21 GlaxoSmithKline Biologicals SA Komplement-vermittelte antikörper-abhängige und opsonische bakterienassays mit hohem durchlauf
US8658176B2 (en) 2009-06-22 2014-02-25 National Health Research Institutes Lipidated tumor-associated antigens and immunotherapeutic compositions
EP2470204B1 (de) 2009-08-27 2015-12-16 GlaxoSmithKline Biologicals SA Hybridpolypeptide mit meningokokken-fhbp-sequenzen
WO2011024071A1 (en) 2009-08-27 2011-03-03 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
WO2011026111A1 (en) 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oral delivery of a vaccine to the large intestine to induce mucosal immunity
SG178954A1 (en) 2009-09-02 2012-04-27 Novartis Ag Immunogenic compositions including tlr activity modulators
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
CA2779798C (en) 2009-09-30 2019-03-19 Novartis Ag Conjugation of staphylococcus aureus type 5 and type 8 capsular polysaccharides
WO2011039631A2 (en) 2009-09-30 2011-04-07 Novartis Ag Expression of meningococcal fhbp polypeptides
WO2011051893A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
LT2493498T (lt) 2009-10-30 2017-05-25 Glaxosmithkline Biologicals Sa Staphylococcus aureus 5 tipo ir 8 tipo kapsulinių sacharidų gryninimas
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
SG181712A1 (en) 2009-12-15 2012-07-30 Novartis Ag Homogeneous suspension of immunopotentiating compounds and uses thereof
BR112012022800A2 (pt) 2010-03-11 2018-05-15 Glaxosmithkline Biologicals Sa composição imunogênica ou vacina, cepa bacteriana gram-negativa geneticamente engenheirada, métodos para o tratamento ou prevenção de infecção ou doença, para produzir uma composição imunogênica ou uma vacina, e para preparar uma imunoglobulina, preparação da imunoglobulina, e, preparação farmacêutica
CA2793510A1 (en) 2010-03-18 2012-02-16 Novartis Ag Adjuvanted vaccines for serogroup b meningococcus
WO2011119759A1 (en) 2010-03-23 2011-09-29 Irm Llc Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.
BR122022015250B1 (pt) 2010-03-30 2023-11-07 Children´S Hospital & Research Center At Oakland Composições imunogênicas e seus usos
EP2556377B1 (de) 2010-04-08 2017-07-12 University of Pittsburgh - Of the Commonwealth System of Higher Education Zellenassay mit b-zellen-antigenen
EP2575988A1 (de) 2010-05-28 2013-04-10 Tetris Online, Inc. Interaktive, hybride und asynchrone computerspiel-infrastruktur
WO2011161653A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
PL3246044T3 (pl) 2010-08-23 2021-08-23 Wyeth Llc Stabilne preparaty antygenów rLP2086 Neisseria meningitidis
GB201014967D0 (en) * 2010-09-09 2010-10-20 Univ Southampton Composition
US20120070457A1 (en) * 2010-09-10 2012-03-22 J. Craig Venter Institute, Inc. Polypeptides from neisseria meningitidis
BR112013005626B1 (pt) 2010-09-10 2022-07-26 Glaxosmithkline Biologicals Sa Meningococo, processo para a preparação de uma cepa meningocócica, vesículas de membrana externa, composição farmacêutica imunogênica, e, uso de uma composição
CA2809758C (en) 2010-09-10 2021-07-13 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
TW201221642A (en) 2010-11-15 2012-06-01 Nat Health Research Institutes Method of producing lipidated polypeptides
TWI507413B (zh) 2010-11-15 2015-11-11 Nat Health Research Institutes 脂質化多抗原表位疫苗
WO2012085668A2 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
EP2491788B1 (de) 2011-02-25 2015-12-23 Kraft Foods R & D, Inc. Lebensmittelprodukt mit einem formkörper
US20140112950A1 (en) 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
EP2707009A1 (de) 2011-05-12 2014-03-19 Novartis AG Antipyretika zur verbesserung der verträglichkeit von impfstoffen auf vesikelbasis
EP2723378A4 (de) 2011-06-24 2015-01-28 Epitogenesis Inc Pharmazeutische zusammensetzungen mit einer kombination aus ausgewählten trägern, vitaminen, tanninen und flavonoiden als antigenspezifischen immunmodulatoren
JP2014529407A (ja) 2011-08-31 2014-11-13 チルドレンズホスピタル アンド リサーチ センター オークランド ナイセリアにおいて抗原の発現を促進するための操作された配列および使用方法
EP2776069A1 (de) 2011-11-07 2014-09-17 Novartis AG Trägermolekül mit einem spr0096- und einem spr2021-antigen
AU2011384634A1 (en) 2011-12-29 2014-06-19 Novartis Ag Adjuvanted combinations of meningococcal factor H binding proteins
CN104114706A (zh) 2012-02-02 2014-10-22 诺华股份有限公司 用于脑膜炎球菌中增加的蛋白表达的启动子
US10598666B2 (en) 2012-03-08 2020-03-24 Glaxosmithkline Biologicals Sa In vitro potency assay for protein-based meningococcal vaccines
JP2015509963A (ja) 2012-03-08 2015-04-02 ノバルティス アーゲー Ｔｌｒ４アゴニストを含む混合ワクチン
CN104334187B (zh) 2012-03-09 2017-04-05 辉瑞公司 脑膜炎双球菌组合物及其方法
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CA2876138C (en) 2012-06-14 2023-09-19 Novartis Ag Vaccines for serogroup x meningococcus
US10000545B2 (en) 2012-07-27 2018-06-19 Institut National De La Sante Et De La Recherche Medicale CD147 as receptor for pilus-mediated adhesion of Meningococci to vascular endothelia
US9526776B2 (en) 2012-09-06 2016-12-27 Glaxosmithkline Biologicals Sa Combination vaccines with serogroup B meningococcus and D/T/P
US9855325B2 (en) 2012-10-03 2018-01-02 Glaxosmithkline Biologicals Sa Immunogenic composition
EP2919806A4 (de) * 2012-11-16 2016-06-22 Jackson H M Found Military Med Aus gonokokken stammende mtre-peptide und impfstoffe
EP2950819B1 (de) 2013-02-01 2018-03-28 GlaxoSmithKline Biologicals SA Intradermale abgabe von immunologischen zusammensetzungen mit toll-like-rezeptor-agonisten
JP6446377B2 (ja) 2013-03-08 2018-12-26 ファイザー・インク 免疫原性融合ポリペプチド
AU2014296027A1 (en) 2013-08-02 2016-02-04 Children's Hospital & Research Center At Oakland Non-naturally occurring factor H binding proteins (fHbp) and methods of use thereof
CN105492021B (zh) 2013-09-08 2018-12-04 辉瑞公司 脑膜炎奈瑟氏球菌组合物及其方法
WO2015128480A1 (en) 2014-02-28 2015-09-03 Novartis Ag Modified meningococcal fhbp polypeptides
ES2922554T3 (es) 2014-07-23 2022-09-16 Childrens Hospital & Res Center At Oakland Variantes de proteínas de unión al factor H y métodos de uso de las mismas
WO2016132294A1 (en) 2015-02-19 2016-08-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US11066453B2 (en) 2015-05-18 2021-07-20 Biomvis Srl Immunogenic compositions containing bacterial outer membrane vesicles and therapeutic uses thereof
JP7005504B2 (ja) 2016-02-22 2022-01-21 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー 生体分子の固定化方法
EP3439704A1 (de) 2016-04-05 2019-02-13 GSK Vaccines S.r.l. Immunogene zusammensetzungen
EP3263695A1 (de) 2016-06-29 2018-01-03 GlaxoSmithKline Biologicals SA Immunogene zusammensetzungen
WO2018042017A2 (en) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
IL303108B1 (en) 2017-01-31 2024-03-01 Pfizer NEISSERIA MENINGITIDIS preparations and methods therefor
BR112020001255A2 (pt) 2017-07-21 2020-07-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services composições imunogênicas de neisseria meningitidis
WO2019126197A1 (en) 2017-12-18 2019-06-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bacterial polysaccharide-conjugated carrier proteins and use thereof
MX2020008417A (es) 2018-02-12 2020-11-11 Inimmune Corp Ligandos de receptores de tipo toll.
CN108950056B (zh) * 2018-08-30 2021-08-20 安徽农业大学 与小麦种子休眠/穗发芽抗性相关的caps标记及其检测方法
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
GB2583070B (en) 2019-03-20 2023-09-13 Schlumberger Technology Bv Viscosification of aqueous solutions
WO2020188343A1 (en) * 2019-03-21 2020-09-24 Fonterra Co-Operative Group Limited Compositions comprising polar lipids for maintaining or increasing mobility and vitality
EP4007600A4 (de) * 2019-08-01 2023-08-23 Trustees of Tufts College Impfstoffzusammensetzung und verfahren zur auswahl von antigenen
US11865981B2 (en) * 2020-05-05 2024-01-09 Thor Tech, Inc. Wire loom support
IL302449A (en) 2020-11-04 2023-06-01 Eligo Bioscience CUTIBACTERIUM ACNES PHAGES RECOMBINANT, the production method and their uses
CN113773366B (zh) * 2021-07-27 2023-06-16 四川丽妍工坊生物科技有限公司 一种抗炎多肽bmp14及其制备方法和应用
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay
GB202208089D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202208093D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition

Family Cites Families (222)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2386796A (en) 1942-08-05 1945-10-16 Bond Crown & Cork Co Extruding device
DE2855719A1 (de) 1978-12-22 1980-07-10 Siemens Ag Zahnaerztliche handstueckanordnung
US4336336A (en) 1979-01-12 1982-06-22 President And Fellows Of Harvard College Fused gene and method of making and using same
AU545912B2 (en) 1980-03-10 1985-08-08 Cetus Corporation Cloned heterologous jive products in bacillies
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
AU8300282A (en) 1981-04-29 1982-11-04 Biogen N.V. Bacillus cloning vectors and method of expressing foreign dna
US4551433A (en) 1981-05-18 1985-11-05 Genentech, Inc. Microbial hybrid promoters
US4405712A (en) 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4876197A (en) 1983-02-22 1989-10-24 Chiron Corporation Eukaryotic regulatable transcription
CA1341116C (en) 1983-02-22 2000-10-17 Rae Lyn Burke Yeast expression systems with vectors having gapdh or pyk promoters and synthesis or foreign protein
JPS59166086A (ja) 1983-03-09 1984-09-19 Teruhiko Beppu 新規な発現型プラスミドとそれらを用いて仔牛プロキモシン遺伝子を大腸菌内で発現させる方法
US4546083A (en) 1983-04-22 1985-10-08 Stolle Research & Development Corporation Method and device for cell culture growth
US4588684A (en) 1983-04-26 1986-05-13 Chiron Corporation a-Factor and its processing signals
JPS59205983A (ja) 1983-04-28 1984-11-21 ジエネツクス・コ−ポレイシヨン 異種遺伝子を原核微生物で発現させる方法
US4663280A (en) 1983-05-19 1987-05-05 Public Health Research Institute Of The City Of New York Expression and secretion vectors and method of constructing vectors
EP0127839B1 (de) 1983-05-27 1992-07-15 THE TEXAS A&M UNIVERSITY SYSTEM Verfahren zur Herstellung eines rekombinanten Baculovirus-Expressionsvektors
US4689406A (en) 1983-08-10 1987-08-25 Amgen Enhancement of microbial expression of polypeptides
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
JPS6054685A (ja) 1983-09-02 1985-03-29 Suntory Ltd 改良発現ベクタ−およびその利用
EP0136907A3 (de) 1983-10-03 1986-12-30 Genentech, Inc. Xenogeneisches Expressionskontrollsystem, Verfahren zu dessen Verwendung, dieses enthaltende Expressionsvektoren, mit denselben transformierte Zellen und daraus hergestellte heterolose Proteine
ZA848495B (en) 1984-01-31 1985-09-25 Idaho Res Found Production of polypeptides in insect cells
US4880734A (en) 1984-05-11 1989-11-14 Chiron Corporation Eukaryotic regulatable transcription
ATE102250T1 (de) 1984-05-11 1994-03-15 Chiron Corp Erhoehte hefetranskription unter verwendung einer hybridkonstruktion der promotorregion.
US5288641A (en) 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
CA1282721C (en) 1984-06-04 1991-04-09 Bernard Roizman Herpes simplex virus as a vector
US4738921A (en) 1984-09-27 1988-04-19 Eli Lilly And Company Derivative of the tryptophan operon for expression of fused gene products
US4745056A (en) 1984-10-23 1988-05-17 Biotechnica International, Inc. Streptomyces secretion vector
US4837148A (en) 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
US4762915A (en) 1985-01-18 1988-08-09 Liposome Technology, Inc. Protein-liposome conjugates
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
EP0196056B1 (de) 1985-03-28 1991-05-22 Chiron Corporation Expression durch Verwendung von Fusionsgenen für Proteinproduktion
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4865974A (en) 1985-09-20 1989-09-12 Cetus Corporation Bacterial methionine N-terminal peptidase
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
JPS6296086A (ja) 1985-10-21 1987-05-02 Agency Of Ind Science & Technol 複合プラスミド
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
ES2061482T3 (es) 1986-05-02 1994-12-16 Gist Brocades Nv Metodo para la identificacion de secuencias de señal secretora para sintesis de proteina extracelular en bacillus.
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
DE3752372T2 (de) 1986-10-02 2004-06-24 Massachusetts Institute Of Technology, Cambridge Verfahren zur regulierung der metabolischen stabilität von proteinen
EP0273116A3 (de) 1986-10-09 1990-05-02 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Gonokokken- und Meningokokken-Polypeptide, Impfstoffe und Diagnostiken
US5514581A (en) * 1986-11-04 1996-05-07 Protein Polymer Technologies, Inc. Functional recombinantly prepared synthetic protein polymer
JPS63123383A (ja) 1986-11-11 1988-05-27 Mitsubishi Kasei Corp ハイブリツドプロモ−タ−、発現調節ｄｎａ配列および発現ベクタ−
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
JP2795850B2 (ja) 1987-03-23 1998-09-10 ザイモジェネティクス，インコーポレイティド 酵母発現ベクター
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
DK463887D0 (da) 1987-09-07 1987-09-07 Novo Industri As Gaerleader
DE3852823T2 (de) 1987-09-11 1995-05-24 Whitehead Biomedical Inst Transduktionsveränderte fibroblasten und ihre anwendung.
US5124246A (en) 1987-10-15 1992-06-23 Chiron Corporation Nucleic acid multimers and amplified nucleic acid hybridization assays using same
US4929555A (en) 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
DE318216T1 (de) 1987-11-18 1990-06-13 Chiron Corp., Emeryville, Calif. Nanbv-diagnostika und vakzine.
JPH01144977A (ja) * 1987-11-30 1989-06-07 Agency Of Ind Science & Technol 新規組換えプラスミドｐＴＰＧＩＦ２
WO1989005349A1 (en) 1987-12-09 1989-06-15 The Australian National University Method of combating viral infections
CA1340772C (en) 1987-12-30 1999-09-28 Patricia Tekamp-Olson Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences
US4973551A (en) 1988-01-15 1990-11-27 Merck & Co., Inc. Vector for the expression of fusion proteins and protein immunogens
US5662896A (en) 1988-03-21 1997-09-02 Chiron Viagene, Inc. Compositions and methods for cancer immunotherapy
CN1038306A (zh) 1988-03-21 1989-12-27 维吉恩公司 重组反转录病毒
US5591624A (en) 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
US5206152A (en) 1988-04-08 1993-04-27 Arch Development Corporation Cloning and expression of early growth regulatory protein genes
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
CA1339354C (en) 1988-09-01 1997-08-26 The Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
ES2070312T5 (es) 1988-12-19 2003-05-16 American Cyanamid Co Vacuna de proteina de membrana exterior meningococica de clase 1.
NL8803111A (nl) 1988-12-19 1990-07-16 Nederlanden Staat Multivalent meningococcen klasse i buitenmembraaneiwit vaccin.
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
EP0448650A4 (en) 1989-02-01 1992-05-13 The General Hospital Corporation Herpes simplex virus type i expression vector
JP3140757B2 (ja) 1989-02-06 2001-03-05 デイナ・フアーバー・キヤンサー・インステイテユート パッケージング欠陥ｈｉｖプロウイルス、細胞系及びその使用
KR920701453A (ko) 1989-03-17 1992-08-11 미리엄 디. 멕코나헤이 유전자발현의 외부조절
ES2116269T3 (es) 1989-03-21 1998-07-16 Vical Inc Expresion de secuencias exogenas de polinucleotidos en un vertebrado.
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
JPH04507435A (ja) 1989-08-15 1992-12-24 パスミンコ　オーストラリア　リミテッド 溶融鉛への亜鉛蒸気の吸収
EP0845537A1 (de) 1989-08-18 1998-06-03 Chiron Corporation Rekombinante Retroviren, die einen Prodrug exprimieren, zur Behandlung von GVhD
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
AU7007491A (en) 1990-02-02 1991-08-08 Schweiz. Serum- & Impfinstitut Bern Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses
ZA911974B (en) 1990-03-21 1994-08-22 Res Dev Foundation Heterovesicular liposomes
CA2039921A1 (en) 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
AU7906691A (en) 1990-05-23 1991-12-10 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Adeno-associated virus (aav)-based eucaryotic vectors
US5149655A (en) 1990-06-21 1992-09-22 Agracetus, Inc. Apparatus for genetic transformation
CU22302A1 (es) * 1990-09-07 1995-01-31 Cigb Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales
IE912559A1 (en) 1990-07-19 1992-01-29 Merck & Co Inc The class ii protein of the outer membrane of neisseria¹meningitidis, and vaccines containing same
EP0541693B1 (de) 1990-07-27 1998-12-09 Chiron Corporation Grosse kammförmig verzweigte polynukleotide
EP0546118B1 (de) * 1990-08-23 2003-10-29 University Of North Carolina At Chapel Hill Transferrin bindende proteine aus neisseria-gonorrhoeae und neisseria-meningitidis
AU665176B2 (en) 1990-09-21 1995-12-21 Novartis Vaccines And Diagnostics, Inc. Packaging cells
WO1992007945A1 (en) 1990-10-30 1992-05-14 Dana Farber Cancer Institute Cell type specific alteration of levels of gene products in neural cells
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
SE9003978D0 (sv) 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
WO1992011033A1 (en) 1990-12-20 1992-07-09 Arch Development Corporation Control of gene expression by ionizing radiation
AU1411492A (en) * 1991-01-31 1992-09-07 Washington University Polypeptides and polynucleotides useful for the diagnosis and treatment of pathogenic neisseria
WO1992016643A1 (en) 1991-03-14 1992-10-01 Imclone Systems Incorporated Recombinant hybrid porin epitopes
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
JPH0515375A (ja) * 1991-07-11 1993-01-26 Kanegafuchi Chem Ind Co Ltd ヒト内因子をコードするｄｎａ配列
JP3534749B2 (ja) 1991-08-20 2004-06-07 アメリカ合衆国 アデノウイルスが介在する胃腸管への遺伝子の輸送
FR2681786A1 (fr) 1991-09-27 1993-04-02 Centre Nat Rech Scient Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires.
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
IL103059A0 (en) 1991-09-30 1993-02-21 Boehringer Ingelheim Int Conjugates for introducing nucleic acid into higher eucaryotic cells
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
JPH07507854A (ja) 1991-12-23 1995-08-31 ツォッヒェ，ミヒャエル 油除去装置を備えたエンジン
EP0625049A4 (de) 1992-01-23 1995-07-12 Vical Inc Ex vivo gentransfer.
WO1993015115A1 (en) * 1992-01-24 1993-08-05 Cornell Research Foundation, Inc. E. coli dna polymerase iii holoenzyme and subunits
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
WO1993025234A1 (en) 1992-06-08 1993-12-23 The Regents Of The University Of California Methods and compositions for targeting specific tissue
CA2137361A1 (en) 1992-06-10 1993-12-23 W. French Anderson Vector particles resistant to inactivation by human serum
WO1993025685A1 (en) * 1992-06-12 1993-12-23 Massachusetts Institute Of Technology Cloning and characterization of the cell death genes ced-3 and ced-4
FR2692592B1 (fr) 1992-06-19 1995-03-31 Pasteur Merieux Serums Vacc Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis et procédés les exprimant.
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
GB9216851D0 (en) 1992-08-07 1992-09-23 Univ Manitoba Dna sequences of rat probasin gene
EP0669987B1 (de) 1992-09-25 2008-08-13 Aventis Pharma S.A. Adenovirus vektoren für die übertragung fremder gene in zellen des zentralen nervensystems, insbesondere im gehirn
AU5403594A (en) * 1992-10-07 1994-04-26 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University Pilin variants and uses thereof
ATE307212T1 (de) 1992-11-18 2005-11-15 Arch Dev Corp Adenovirus-gelenkter gen-transfer zum herz-und glatten vaskulären muskel
EP0673431A1 (de) 1992-12-03 1995-09-27 Genzyme Corporation GENTHERAPIE DER MYKOVISCIDOSES (kystic fibroses)
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US5348358A (en) 1993-02-22 1994-09-20 Selick David A Contact lens insertion tool
DE4311651A1 (de) 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
DK0695169T3 (da) 1993-04-22 2003-03-17 Skyepharma Inc Multivesikulære liposomer med indkapslet cyclodextrin og farmakologisk aktive forbindelser samt fremgangsmåder til anvendelse af disse
DE69423383T2 (de) 1993-05-13 2000-08-24 American Cyanamid Co Herstellung und Verwendungen von LOS-verminderten Aussenmembran-Proteinen von Gram-negativen Kokken
WO1994028157A1 (en) 1993-05-26 1994-12-08 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Fusion proteins containing adeno-associated virus rep protein and bacterial protein
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US6479055B1 (en) * 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
ES2249761T3 (es) 1993-06-24 2006-04-01 Advec Inc. Vectores de adenovirus para terapia genica.
AU7264694A (en) 1993-07-13 1995-02-13 Rhone-Poulenc Rorer S.A. Defective adenovirus vectors and use thereof in gene therapy
US5439808A (en) 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
JPH09501564A (ja) 1993-07-27 1997-02-18 ザ・ウイスター・インステイテユート・オブ・アナトミー・アンド・バイオロジー 改質ｄｎａウイルスベクターおよびその使用
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5362865A (en) 1993-09-02 1994-11-08 Monsanto Company Enhanced expression in plants using non-translated leader sequences
ES2328424T3 (es) 1993-09-15 2009-11-12 Novartis Vaccines And Diagnostics, Inc. Vectores de alfavirus recombinantes.
FR2710536B1 (fr) 1993-09-29 1995-12-22 Transgene Sa Usage anti-cancéreux d'un vecteur viral comportant un gène modulateur de la réponse immunitaire et/ou inflammatoire.
EP0723460A4 (de) 1993-10-01 1998-09-30 Us Health Gentherapie für das nervensystems
CN1263864C (zh) 1993-10-25 2006-07-12 坎吉公司 重组腺病毒载体及其使用方法
US5693506A (en) 1993-11-16 1997-12-02 The Regents Of The University Of California Process for protein production in plants
PT729351E (pt) 1993-11-16 2000-12-29 Skyepharma Inc Vesiculas com libertacao controlada de activos
FR2712603B1 (fr) 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
US5550213A (en) * 1993-12-27 1996-08-27 Rutgers, The State University Of New Jersey Inhibitors of urokinase plasminogen activator
JPH07241786A (ja) 1994-03-08 1995-09-19 Fanuc Ltd 産業用ロボットの制御装置
US6780406B1 (en) 1994-03-21 2004-08-24 The Regents Of The University Of Michigan Inhibition of vascular smooth muscle cell proliferation administering a thymidine kinase gene
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
EP0710118B1 (de) 1994-04-20 1998-11-25 U.S. Department Of The Army Impfstoff gegen gram-negative bakterielle infektionen
JPH10507061A (ja) 1994-04-28 1998-07-14 ザ ユニバーシティ オブ ミシガン アデノウイルス中にパッケージされたプラスミドｄｎａを用いる遺伝子送達ベクターおよびパッケージング細胞株
ATE381624T1 (de) 1994-05-09 2008-01-15 Oxford Biomedica Ltd Retrovirale vektoren mit verminderter rekombinationsrate
FR2720408B1 (fr) 1994-05-31 1996-08-14 Pasteur Merieux Serums Vacc Fragments Tbp2 de Neisseria meningitidis.
ATE336587T1 (de) 1994-06-10 2006-09-15 Genvec Inc Adenoviren-vektor systeme und zelllinien
FR2722210B1 (fr) 1994-07-08 1996-08-14 Rhone Poulenc Rorer Sa Nouvelles streptogramines et procede de preparation de streptogramines par mutasynthese
FR2723588B1 (fr) 1994-08-12 1996-09-20 Rhone Poulenc Rorer Sa Adenovirus comprenant un gene codant pour la glutathion peroxydase
IL117483A (en) * 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US6265567B1 (en) * 1995-04-07 2001-07-24 University Of North Carolina At Chapel Hill Isolated FrpB nucleic acid molecule
AU5552396A (en) * 1995-04-21 1996-11-07 Human Genome Sciences, Inc. Nucleotide sequence of the haemophilus influenzae rd genome, fragments thereof, and uses thereof
JPH11505128A (ja) 1995-05-22 1999-05-18 カイロン コーポレイション キメラインテグラーゼタンパク質に媒介される真核生物ゲノム中へのベクター構築物の位置特異的組み込み
WO1996040893A1 (en) * 1995-06-07 1996-12-19 Astra Aktiebolag Nucleic acid and amino acid sequences relating to helicobacter pylori for diagnostics and therapeutics
FR2739624B1 (fr) 1995-10-10 1997-12-05 Pasteur Merieux Serums Vacc Nouvelle sous-unite tbp2 de neisseria meningitidis
US6737248B2 (en) * 1996-01-05 2004-05-18 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and sequences
CA2242200A1 (en) * 1996-01-26 1997-07-31 Innogenetics N.V. Toxoplasma gondii antigen tg20
PL328096A1 (en) 1996-02-01 1999-01-04 North American Vaccine Expression of external membrane (mb3) protein of neisseria meningitidis of b group in yeasts and vaccines
US5753235A (en) 1996-02-15 1998-05-19 Heska Corporation Recombinant canine herpesviruses
JP2000501621A (ja) * 1996-03-29 2000-02-15 アストラ・アクテイエボラグ ヘリコバクターピロリに関係した核酸及びアミノ酸配列並びにそれらのワクチン組成物
ATE198050T1 (de) * 1996-05-10 2000-12-15 Xoma Technology Ltd Therapeutische anwendungen von bpi-protein- produkten zur behandlung von humaner meningococcämia
US6096529A (en) * 1996-06-10 2000-08-01 National Research Council Of Canada Recombinant α-2,3-sialyltransferases and their uses
FR2751000B1 (fr) * 1996-07-12 1998-10-30 Inst Nat Sante Rech Med Adn specifiques des bacteries de l'espece neisseria meningitidis, leurs procedes d'obtention et leurs applications biologiques
EP0818465A1 (de) * 1996-07-12 1998-01-14 Institute of Molecular Biotechnology (IMB) Department of Genome Analysis Genomische Sequenz des symbiontischen Plasmids von Rhizobium sp.NGR234
US6472518B1 (en) 1996-10-24 2002-10-29 Centers For Disease Control And Prevention, As Represented By The Secretary, Department Of Health And Human Services Invasion associated genes from Neisseria meningitidis serogroup B
BR9714160A (pt) * 1996-12-20 2000-05-02 Univ Texas Antìgenos uspa1 e uspa2 de moraxella catarrhalis
US5763589A (en) * 1997-01-09 1998-06-09 Incyte Pharmaceuticals, Inc. Human membrane protein
US6914131B1 (en) 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
EP1900818A3 (de) * 1997-11-06 2008-06-11 Novartis Vaccines and Diagnostics S.r.l. Neissersche Antigene
GB9726398D0 (en) 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
AU1979599A (en) 1998-01-14 1999-08-02 Chiron S.P.A. (neisseria meningitidis) antigens
EP2261356A3 (de) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Antigene und Zusammensetzungen gegen Neisseria meningitidis
US20070026021A1 (en) 1998-05-01 2007-02-01 Chiron S.R.I. Neisseria meningitidis antigens and compositions
EP1559795A3 (de) 1998-10-09 2005-11-09 Chiron Corporation Genomische Sequenzen von Neisseria und Verfahren zu ihrer Verwendung
US6214566B1 (en) * 1998-11-16 2001-04-10 The Administrators Of The Tulane Educational Fund Method for detecting anti-squalene antibodies
WO2000034482A2 (en) * 1998-12-08 2000-06-15 Smithkline Beecham Biologicals S.A. Novel compounds derived from neisseria meningitidis
GB9902084D0 (en) * 1999-01-29 1999-03-24 Smithkline Beecham Biolog Novel compounds
EP2270169A3 (de) * 1999-03-12 2011-06-15 GlaxoSmithKline Biologicals SA Antigene Polypeptide aus Neisseria Meningitidis, dafür kodierende Polynukleotide und entsprechende schützende Antikörper
DE60042114D1 (de) 1999-04-30 2009-06-10 Craig J Venter Inst Inc Genomische sequenzen von neisseria und verfahren zu ihrer verwendung
CA2372235A1 (en) * 1999-04-30 2000-11-09 Rino Rappuoli Conserved neisserial antigens
CN100338218C (zh) 1999-05-19 2007-09-19 启龙股份公司 组合式奈瑟球菌组合物
EP2975127A1 (de) 1999-10-29 2016-01-20 GlaxoSmithKline Biologicals SA Neisseria antigenpeptide
PT1248647E (pt) * 2000-01-17 2010-11-18 Novartis Vaccines & Diagnostics Srl Vacina de vesícula da membrana externa (omv) compreendendo proteínas de membrana externa de n. meningitidis do serogrupo b
CN1419564A (zh) 2000-01-25 2003-05-21 昆士兰大学 包含脑膜炎奈瑟氏球菌表面抗原NhhA的保守区域的蛋白质
WO2001064922A2 (en) 2000-02-28 2001-09-07 Chiron Spa Heterologous expression of neisserial proteins
ES2276788T3 (es) 2000-05-10 2007-07-01 Sanofi Pasteur Limited Polipeptidos inmunogenos codificados por minigenes mage y sus utilizaciones.
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
EP1409013B1 (de) 2001-07-26 2009-11-18 Novartis Vaccines and Diagnostics S.r.l. Aluminiumadjuvans und histidin enthaltende impstoffe
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
DE60236596D1 (de) 2001-07-27 2010-07-15 Novartis Vaccines & Diagnostic Antikörper gegen das meningokokken adhäsin app
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
EP1524992B1 (de) 2002-08-02 2015-03-04 GlaxoSmithKline Biologicals s.a. Impfstoffzusamensetzungen die l2 und/oder l3 immunotyp lipooligosaccharids von lgtb- neisseria meningitidis enthalten
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
PT2351579T (pt) 2002-10-11 2016-12-22 Novartis Vaccines And Diagnostics S R L Vacinas polipeptídicas para proteção ampla contra linhagens meningocócicas hipervirulentas
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
US20070148729A1 (en) 2003-01-15 2007-06-28 Farley John E Methods for increasing neisseria protein expression and compositions thereof
WO2004067030A2 (en) 2003-01-30 2004-08-12 Chiron Srl Injectable vaccines against multiple meningococcal serogroups
WO2004094596A2 (en) 2003-04-16 2004-11-04 Wyeth Holdings Corporation Novel immunogenic compositions for the prevention and treatment of meningococcal disease
ES2397923T3 (es) 2003-10-02 2013-03-12 Novartis Ag Vacunas líquidas para múltiples serogrupos meningocócicos
GB0409748D0 (en) 2004-04-30 2004-06-09 Chiron Srl Lactoferrin cleavage
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
RU2432962C2 (ru) 2005-01-27 2011-11-10 Чилдрен'З Хоспитал Энд Рисерч Сентер Эт Окленд Вакцины с использованием везикул на основе gna 1870 широкого спектра действия для профилактики заболеваний, вызываемых neisseria meningitidis
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
CN101479293A (zh) * 2006-06-29 2009-07-08 诺华有限公司 脑膜炎奈瑟球菌多肽
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
WO2008125985A2 (en) 2007-04-11 2008-10-23 Novartis Ag Blocking interaction between pathogen factors and factor h to inhibit hemorrhagic syndromes
ES2555786T3 (es) 2007-06-04 2016-01-08 Glaxosmithkline Biologicals Sa Formulación de vacunas contra la meningitis
EP2886551A3 (de) 2008-02-21 2015-09-23 Novartis AG Meningokokken-FHBP-Polypeptide
US9511131B2 (en) 2008-03-10 2016-12-06 Children's Hospital & Research Center Oakland Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
US8470340B2 (en) 2008-09-03 2013-06-25 Children's Hospital & Research Center Oakland Peptides presenting an epitope of a domain of factor H binding protein and methods of use
IT1394288B1 (it) 2008-09-12 2012-06-06 Novartis Vaccines & Diagnostic Immunogeni di proteine che legano il fattore h.
GB0819633D0 (en) 2008-10-25 2008-12-03 Isis Innovation Composition
US9714465B2 (en) 2008-12-01 2017-07-25 Applied Materials, Inc. Gas distribution blocker apparatus
JP5597245B2 (ja) * 2009-03-24 2014-10-01 ノバルティス アーゲー アジュバント添加した髄膜炎菌ｈ因子結合タンパク質
BR112013005626B1 (pt) 2010-09-10 2022-07-26 Glaxosmithkline Biologicals Sa Meningococo, processo para a preparação de uma cepa meningocócica, vesículas de membrana externa, composição farmacêutica imunogênica, e, uso de uma composição

Also Published As

Publication number Publication date
EP2261345A3 (de) 2012-01-11
EP2261350A3 (de) 2012-01-04
EP2261340A2 (de) 2010-12-15
JP2013252140A (ja) 2013-12-19
EP2261344A2 (de) 2010-12-15
EP2261340B1 (de) 2017-03-08
DE69937419T2 (de) 2008-07-24
JP2012191945A (ja) 2012-10-11
JP2010166916A (ja) 2010-08-05
EP2261351A3 (de) 2012-01-11
EP1645631A2 (de) 2006-04-12
PT1944371E (pt) 2015-07-13
EP2261344A3 (de) 2012-01-04
JP6025675B2 (ja) 2016-11-16
EP2261343A3 (de) 2012-01-18
US7988979B2 (en) 2011-08-02
ES2294629T3 (es) 2008-04-01
NZ532665A (en) 2005-11-25
DK1093517T3 (da) 2008-06-23
PT1093517E (pt) 2008-06-12
CN101293920A (zh) 2008-10-29
JP2013255503A (ja) 2013-12-26
WO1999057280A3 (en) 2000-08-24
EP2261355A3 (de) 2012-01-11
US20160030545A1 (en) 2016-02-04
EP2261351A2 (de) 2010-12-15
EP2261346A3 (de) 2012-01-04
EP1944371B1 (de) 2015-03-04
NZ541361A (en) 2008-04-30
JP2017012195A (ja) 2017-01-19
HK1090382A1 (en) 2006-12-22
DE69938302D1 (de) 2008-04-17
EP2261349A2 (de) 2010-12-15
EP2261338A3 (de) 2012-01-04
EP2261338A2 (de) 2010-12-15
CY1109649T1 (el) 2014-08-13
EP2261342A2 (de) 2010-12-15
EP2261348A2 (de) 2010-12-15
JP2016222709A (ja) 2016-12-28
ES2537575T3 (es) 2015-06-09
EP2261348A3 (de) 2012-01-25
EP2261341A2 (de) 2010-12-15
EP2261349A3 (de) 2012-01-11
US20150086582A1 (en) 2015-03-26
EP2261343A2 (de) 2010-12-15
WO1999057280A2 (en) 1999-11-11
DE69937419D1 (de) 2007-12-06
EP2261356A2 (de) 2010-12-15
ATE376591T1 (de) 2007-11-15
MX339406B (es) 2016-05-25
BR9910089A (pt) 2004-06-08
EP1093517A2 (de) 2001-04-25
EP2261347A2 (de) 2010-12-15
US20150079124A1 (en) 2015-03-19
EP2261340A3 (de) 2012-01-04
JP2009183306A (ja) 2009-08-20
EP1645631A3 (de) 2006-04-19
EP2261354A3 (de) 2012-01-11
CA2650642A1 (en) 1999-11-11
AU761780B2 (en) 2003-06-12
US20090232820A1 (en) 2009-09-17
EP2261350A2 (de) 2010-12-15
MX343752B (es) 2016-11-22
WO1999057280A9 (en) 2002-08-29
MXPA00010722A (es) 2004-12-03
JP2012191946A (ja) 2012-10-11
EP1944371A2 (de) 2008-07-16
EP2261353A2 (de) 2010-12-15
US9266929B2 (en) 2016-02-23
EP2261352A2 (de) 2010-12-15
US9249196B2 (en) 2016-02-02
EP2261341A3 (de) 2012-01-04
CN100379757C (zh) 2008-04-09
CY1108083T1 (el) 2014-02-12
EP1645631B1 (de) 2007-10-24
AU3967799A (en) 1999-11-23
JP6025674B2 (ja) 2016-11-16
JP5102414B2 (ja) 2012-12-19
EP2261339A2 (de) 2010-12-15
ES2304065T3 (es) 2008-09-01
EP2261357A3 (de) 2012-01-11
MX343744B (es) 2016-11-22
NZ527182A (en) 2004-06-25
US20120164166A1 (en) 2012-06-28
US7576176B1 (en) 2009-08-18
US8524251B2 (en) 2013-09-03
CN1754885A (zh) 2006-04-05
EP2261354A2 (de) 2010-12-15
PT1645631E (pt) 2008-02-04
EP2261356A3 (de) 2012-01-04
CA2330838A1 (en) 1999-11-11
US9249198B2 (en) 2016-02-02
EP2261346A2 (de) 2010-12-15
DE69938302T2 (de) 2009-03-12
EP2261357A2 (de) 2010-12-15
EP2261352A3 (de) 2012-01-04
CN1210305C (zh) 2005-07-13
CN101293920B (zh) 2012-07-18
CN1373806A (zh) 2002-10-09
US20120156236A1 (en) 2012-06-21
NZ508366A (en) 2004-03-26
US20120148616A1 (en) 2012-06-14
EP1944371A3 (de) 2008-10-08
ATE388230T1 (de) 2008-03-15
CA2330838C (en) 2018-12-04
EP2261345A2 (de) 2010-12-15
EP1093517B1 (de) 2008-03-05
US9139621B2 (en) 2015-09-22
JP2004500801A (ja) 2004-01-15
EP2261347A3 (de) 2012-01-11
EP2261353A3 (de) 2012-01-18
EP2261339A3 (de) 2012-01-11
EP2261355A2 (de) 2010-12-15
EP2261339B1 (de) 2017-03-22
EP2261342A3 (de) 2012-01-04
US20120135024A1 (en) 2012-05-31

Similar Documents

Publication Publication Date Title
DK1093517T3 (da) Neisseria-meningitidis-antigener og præparater
CY1110880T1 (el) Αντιγονα neisserial
DK1047784T3 (da) Neissera meningitidis-antigener
DK1185691T3 (da) Genomiske neisseriasekvenser og fremgangmåder til anvendelse deraf
MXPA01003557A (es) Secuencias genomicas de neisseria y metodos para su uso.